DOCSLIB.ORG

Annual Report 2010 Annual Report 2010 15/03/2011 14:26 Page FC1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2010 Annual Report 2010 15/03/2011 14:26 Page FC1 8100 Annual Report 2010_Annual Report 2010 15/03/2011 14:26 Page FC1 Shire plc Annual ReportShire and Accounts 2010 Shire plc Annual Report and Accounts 2010 Delivering value Delivering value www.shire.com 8100 Annual Report 2010_Annual Report 2010 15/03/2011 14:26 Page IFC1 Shire plc Annual Repo Shire trademarks The following are trademarks either owned or licensed by Shire plc or companies within the Shire group (the ‘Group’) which are the subject of trademark registrations in certain territories, or which are owned by third-parties as indicated and referred to in this Annual Report: ADDERALL XR® (mixed salts of a single entity amphetamine) ADDERALL® (mixed salts of a single entity amphetamine) APRISO® (trademark of Salix Pharmaceuticals, Ltd. (‘Salix’)) ASACOL® (trademark of Medeva Pharma Suisse AG (used under license by Warner Chilcott Company, LLC (‘Warner Chilcott’))) ATRIPLA® (trademark of Bristol Myers Squibb Company (‘BMS’) and Gilead Sciences, Inc. (‘Gilead’)) BERINERT P® (trademark of Aventis Behring GmbH) CALCICHEW® range (calcium carbonate with or without vitamin D3) CARBATROL® (carbamazepine extended-release capsules) CEREZYME® (trademark of Genzyme Corporation (‘Genzyme’)) CINRYZE® (trademark of Viropharma Biologics, Inc.) CLAVERSAL® (trademark of Merckle Recordati) COLAZAL® (trademark of Salix Pharmaceuticals, Inc.) COMBIVIR® (trademark of GlaxoSmithKline (‘GSK’)) CONCERTA® (trademark of Alza Corporation (‘Alza’)) DAYTRANA® (trademark of Noven Pharmaceutical Inc. (‘Noven’)) DIPENTUM® (trademark of UCB Pharma Ltd (‘UCB’)) DYNEPO® (trademark of Sanofi-Aventis) ELAPRASE® (idursulfase) EPIVIR® (trademark of GSK) EPIVIR-HBV® (trademark of GSK) EPZICOM®/KIVEXA (EPZICOM) (trademark of GSK) EQUASYM® IR (methylphenidate hydrochloride) EQUASYM® XL (methylphenidate hydrochloride) FABRAZYME® (trademark of Genzyme) FIRAZYR® (icatibant) FOCALIN XR® (trademark of Novartis Pharmaceuticals Corporation (‘Novartis’)) FOSRENOL® (lanthanum carbonate) HEPTOVIR® (trademark of GSK) INTUNIV® (guanfacine extended release) JUVISTA® (trademark of Renovo Limited (‘Renovo’)) KALBITOR® (trademark of Dyax Corporation) KAPVAY® (trademark of Shionogi Pharma, Inc. (‘Shionogi’)) LIALDA® (mesalamine) MEDIKINET® (trademark of Medice Arzneimittel Pütter GmbH & Co. KG (‘Medice’)) METAZYM™ (arylsulfatase-A) METADATE CD® (trademark of UCB) MEZAVANT® (mesalazine) MOVICOL® (trademark of Edra AG, S.A.) PENTASA® (trademark of Ferring A/S Corp (‘Ferring’)) RAZADYNE® (trademark of Johnson & Johnson (‘J&J’)) RAZADYNE® ER (trademark of J&J) REMINYL® (galantamine hydrobromide) (United Kingdom (‘UK’) and Republic of Ireland) (trademark of J&J, excluding UK and Republic of Ireland) REMINYL XL™ (galantamine hydrobromide) (UK and Republic of Ireland) (trademark of J&J, excluding UK and Republic of Ireland) REPLAGAL® (agalsidase alfa) RESOLOR® (prucalopride) RITALIN LA® (trademark of Novartis) RUCONEST® (trademark of Pharming Intellectual Property B.V.) Content online ® SALOFALK (trademark of Dr Falk Pharma) Discover more about our business online at www.shire.com. ® SEASONIQUE (trademark of Barr Laboratories, Inc. (‘Barr’)) Scanning a QR code with your camera phone will directly ® SOLARAZE (trademark of Laboratorios Almirall S.A (‘Almirall’)) link you to mobile content. QR code reader applications STRATTERA® (trademark of Eli Lilly) are available from your App Store. TRIZIVIR® (trademark of GSK) TRUVADA® (trademark of Gilead) VENVANSE (lisdexamfetamine dimesylate) VPRIVTM (velaglucerase alfa) VYVANSE® (lisdexamfetamine dimesylate) XAGRID® (anagrelide hydrochloride) ZAVESCA® (trademark of Actelion Pharmaceuticals, Ltd.) ZEFFIX® (trademark of GSK) 3TC® (trademark of GSK) More online at www.shire.com ›› 8100 Annual Report 2010_Annual Report 2010 15/03/2011 14:26 Page 1 Shire plc Annual Report and Accounts 2010 1 Review of our business Contents Review of our business Already well on our way toward meeting 2 Chairman’s review 4 Chief Executive the ambitious goals we set for ourselves Officer’s review a few years back, we’re now looking even 8 Financial review further ahead at Shire and actively planning for a changing world. We’re intent on delivering innovative products and solutions to meet unmet medical needs and bring value to patients, physicians, payors, and policymakers, for the benefit of society Governance as a whole. We’re keeping patients at the Governance heart of all we do. 38 Board of Directors 40 Directors’ report 45 Corporate governance report 51 Nomination Committee Today, our portfolio is broader and more report 52 Audit, Compliance & balanced. Our international presence Risk Committee report 54 Directors’ remuneration continues to grow. We’re pioneering new report 68 Statement of Directors’ treatments and new delivery platforms responsibilities and seeking to offer patients new hope. Our results speak for themselves. Financial statements Financial statements 69 Independent auditors’ report 70 Consolidated balance sheets 71 Consolidated statements of income 72 Consolidated statements of changes in equity 74 Consolidated statements of comprehensive income 75 Consolidated statements of cash flows 77 Notes to the consolidated financial statements Other information Other information 122 Other information 126 Shire head offices and main operating locations 127 Shareholders information 129 Cautionary statements 130 Parent company financial statements of Shire plc 8100 Annual Report 2010_Annual Report 2010 15/03/2011 14:26 Page 2 2 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Chairman’s review Continuing to provide best-in-class products that provide high value. Matthew Emmens, Chairman 2010 will not go down as the easiest year for the Shire has embarked on an aggressive pharmaceutical industry. The world is ageing, healthcare internationalization campaign—opening new offices costs are soaring, a recessionary global economy around the world, acquiring European companies such put enormous strains on public and personal budgets, as Movetis, and laying the foundation for the launch and payors turned increasingly to low-cost generics of products for diseases not well known or not well and to those branded products with proven societal treated. What is behind these developments? and medical value. What emerging trends has Shire The pharmaceutical industry is a global industry, and it is the been closely monitoring, and why? responsibility of companies like Shire to respond effectively Shire is paying careful attention to the rising pressure to physicians, patients, and payors all around the world. on global healthcare budgets, the higher standards set Shire is taking an approach to growth that is appropriate to by regulatory authorities, and the fact that pharmaceutical its size and mission—leveraging the international presence discovery itself grows increasingly more challenging—trends it has already gained through its work with patients with that are not new, but that certainly are accelerating. Shire rare orphan diseases such as Gaucher disease, Hunter is looking at how smaller companies like itself can continue syndrome and Fabry disease and scaling up as appropriate to take the right risks and to operate with the efficiencies that to serve patients with conditions ranging from attention the environment demands. Shire continues to recognize that deficit hyperactivity disorder (‘ADHD’) to ulcerative colitis. blockbuster products are growing harder and harder to come by and that ever increasing promotional spending cannot Shire has proven its ability to internationalize effectively— be the future. For Shire, the key to success continues to take advantage of internal capabilities and recently hired to be smaller niche markets and targeted therapeutics. new talent to make the most of its pipeline, know-how, and existing portfolio. Online at http://ar2010.shire.com ›› 8100 Annual Report 2010_Annual Report 2010 15/03/2011 14:26 Page 3 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 3 Review of our business 2010 highlights • Total revenues up 15% to $3.5 billion • Core product sales* up $700m (34%) • Total product sales exceeded $3 billion for the first time • Young and balanced portfolio and a strong pipeline *Product sales excluding ADDERALL XR. For the past several years, pharmaceutical companies What talents/resources/strategies does Shire have worked hard to define the word ‘value’—putting bring to this new era? Why are we confident in the increasing emphasis on health economics and health company’s future? technology assessments and broadening the range of Shire continues to be both intuitive in its ability to visualize products/solutions offered to patients and physicians. and adapt to a changing world and scientific in its ability In 2010, the emphasis on value grew even stronger. to discover and support the right opportunities. It is rare to Why? find a pharmaceutical company that is flexible, innovative, Value is ultimately defined by the markets—by ‘customers’. and opportunistic all at the same time—a company that It’s not about a price but rather about the relative value that can achieve 28% growth, in operating income, in an era a patient, a government, or an insurance company sees like this, a company whose people think like entrepreneurs, in a product or service. The tough environment that we find a company that continually evolves its business model. ourselves in demands value. This either means ‘low price’ Shire is fortunate to have the leadership of a strong, or ‘high value’ (meaning the product is worth the price).
Load more

Recommended publications
  • SHIRE PLC (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PLC (Exact name of registrant as specified in its charter) Jersey (Channel Islands) 98-0601486 (State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.) organization) 5 Riverwalk, Citywest Business Campus, Dublin +353 1 429 7700 24, Republic of Ireland (Address of principal executive offices and zip code) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing three NASDAQ Global Select Market Ordinary Shares 5 pence par value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) 1 Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes [X] No [ ] Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes [ ] No [X] Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Annual Report and Accounts 2015 (PDF)
    Adding precision to medicine Annual report and accounts 2015 Overview and strategic report Proteome Sciences in brief Proteome Sciences in brief Proteome Sciences is a leading protein biomarker company specialising Mission and vision Our strategy in proteomics and peptidomics services and applications, and best-in-class Proteomics explained mass spectrometry protein analysis capability. (inside front cover) We have developed a broad portfolio of novel, high value protein biomarker 01 Adding precision to medicine content addressing numerous disease areas where there is unmet need, The future of healthcare is undoubtedly precision medicine or where the ranges of existing diagnostic or therapeutics available have severe 02 Mapping the future of healthcare limitations. These include neurodegenerative diseases, stroke and cancer with precision and where biomarker product candidates have the potential to transform disease 04 Chairman’s Message management and treatment. 05 Key performance indicators 06 Proteome Sciences at a glance Through our novel biomarker discovery both internally and with collaborative 08 Adding precision to medicine partners, our goal is to improve the quality of life for patients with debilitating The precision measures and life-threatening diseases. for better understanding 10 Faster, more efficient and with precision accuracy Mission and vision 12 Our business model Proteome Sciences is a life sciences company delivering content for precision 13 Our measures for success medicine through its services, biomarkers and reagents. We have a strong 14 Strategic Report track record in discovery and innovation supported by intellectual property. Governance and financial statements We use high sensitivity proprietary technologies to detect biomarkers 22 Senior Management Team (differentially expressed proteins from body fluids or tissue in diseases) and to and Board of Directors make rapid assays for testing.
    [Show full text]
  • Inkforgelaunchhandbook.Pdf
    Early Career Researchers.. In hosting this event we would like to say thank you to our industrial partners, who have helped us to shape this program so far. You have done this with dispassionate honesty and enthusiasm, which has been most welcome and encouraging to us all. It has been a steep learning curve for us and we know this is only the beginning. Be reassured that we appreciate the time you are giving and we value hearing your advice and your requests. We may not always get it right but we are genuinely committed to nurturing this partner- ship in a mutually beneficial way that will create a ‟culture of interaction with industry‟ in our institution. Our aim is that the next generation of research leaders will be able to thrive through collaboration, and will be a testament to those who dedicated time to their training. To the academic staff and early career researchers, we would like to encourage you to take up this unique opportunity to increase your network of industrial partners, let them know your strengths and discover their needs. We are entering a new era in the history of universities and the opportunity to network with industrial partners will enable us to en- hance the impact of our research. To those in management positions, we invite you to en- gage with our help in building the InKForge portfolio of events within departments . We hope you will ensure that the early career researchers working with you take part in this process and have the opportunity to learn how it is done.
    [Show full text]
  • The Faculty of Medicine, Dentistry and Health
    Faculty of Medicine Dentistry and Health. Welcome from the Faculty Pro-Vice-Chancellor 3 About the University of Sheffield 4 Teaching in the Faculty of Medicine Dentistry and Health 6 Widening participation 8 Training the next generation: 10 Innovation 11 In partnership with the NHS 12 School of Clinical Dentistry 14 School of Health and Related Research 16 Department of Human Communication Sciences 20 The Medical School 22 MRC Centre for Developmental and Biomedical Genetics 23 Department of Cardiovascular Science 25 Department of Human Metabolism 26 Department of Infection and Immunity 29 Department of Neuroscience 32 Department of Oncology 34 School of Nursing and Midwifery 36 About Sheffield 39 “Together, we offer the potential to develop new interdisciplinary approaches to teaching and research in response to national and global health questions and needs.” Welcome to the Faculty of Medicine, Dentistry and Health It is my great pleasure to introduce you to the Faculty of Medicine, Dentistry and Health at the University of Sheffield. Formed in 2008, the Faculty brings together clinical and health-related subjects across a broad combination of disciplines and expertise. Together, our Faculty includes: • The School of Clinical Dentistry Our schools and departments encompass a broad • The School of Health and Related Research spectrum of expertise, enabling us to examine (ScHARR) problems in new ways and to tackle important • The Department of Human Communication societal questions from a strong position. By bringing Sciences our research experts and acclaimed educators • The Medical School together, we offer the potential to develop new • The Department of Cardiovascular Science interdisciplinary approaches to teaching and • The Department of Human Metabolism research in response to national and global health • The Department of Infection and Immunity questions and needs.
    [Show full text]
  • Making Good Drugs Better
    ANNUAL REPORT AND ACCOUNTS 2008 SkyePharma PLC SkyePharma PLC Making good drugs better Registered Head Office Annual Report and accounts 2008 105 Piccadilly London W1J 7NJ Telephone: 020 7491 1777 Fax: 020 7491 3338 Registered No: 107582 Making good drugs better www.skyepharma.com www.skyepharma.com Stock Exchange Code: SKP 15939 03/ 04/2009 PROOF 11 15939 03/ 04/2009 PROOF 11 15939SKYEPHARMA_CVR.indd 1 3/4/09 09:08:14 OUR BUSINESS OUR GOVERNANCE OUR FINANCIALS IFC Operational Highlights 30 Report of the Directors 66 Consolidated Cash Flow Statement ADVISERS IFC Financial Highlights 35 Corporate Governance 67 Notes to the Consolidated Cash Flow 01 Our Mission 44 Remuneration Report Statement 01 Our Business Model 58 Statement of Directors’ Responsibilities 68 Company Cash Flow Statement 02 Chairman’s Statement 60 Independent Auditors’ Report 69 Notes to the Accounts 04 Chief Executive Officer’s Review 62 Consolidated Income Statement 122 Glossary of Terms 06 Business Review — Products 63 Consolidated Balance Sheet 125 Advisers Auditors Bankers 15 Financial Review 64 Company Balance Sheet Ernst & Young LLP HSBC Bank plc 24 Corporate Social Responsibility 65 Consolidated Statement of Recognised Apex Plaza 70 Pall Mall 26 Products Income and Expense Reading London 28 Directors RG1 1YE SW1 5EZ OPERATIONAL HIGHLIGHTS Solicitors Registrars Fasken Martineau LLP Capita Registrars I United States Phase III clinical programmes for Flutiform™ completed during 2008. 17 Hanover Square Northern House London Woodsome Park I New Drug Application (NDA) for Flutiform™ submitted to FDA in United States on 20 March 2009. W1S 1HU Fenay Bridge I EU filing for Flutiform™ expected in Q1 2010.
    [Show full text]
  • Overview of Ftc Actions in Pharmaceutical Products and Distribution*
    OVERVIEW OF FTC ACTIONS IN PHARMACEUTICAL PRODUCTS AND DISTRIBUTION* Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Kara Monahan Deputy Assistant Director June 2019 * Actions involving health care services and products are contained in a separate document, Overview of FTC Actions in Health Care Services and Products. Information about advisory opinions in the health care and pharmaceutical sectors is contained in the document Topic and Yearly Indices of Health Care Antitrust Advisory Opinions by Commission and by Staff. TABLE OF CONTENTS I. INTRODUCTION ...............................................................................................................1 II. CONDUCT INVOLVING PHARMACEUTICAL PRODUCTS .......................................3 A. Monopolization ........................................................................................................3 B. Agreements Not to Compete ..................................................................................14 III. CONDUCT INVOLVING PHARMACEUTICAL DISTRIBUTION ..............................19 A. Monopolization ......................................................................................................19 B. Agreements on Price and Price-Related Terms .....................................................20 C. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing................................................................................................................26
    [Show full text]
  • Swindon Science Park Capturing Next Generation Industry
    1 SWINDON SCIENCE PARK CAPTURING NEXT GENERATION INDUSTRY PROOF OF EVIDENCE [Type here] 16/05/2021 16 May 2021 PROOF OF EVIDENCE SWINDON SCIENCE PARK: CAPTURING NEXT GENERATION INDUSTRY 1 INTRODUCTION 1.1 Professional Profile: David Lupson, BSc MRICS I am a Chartered Surveyor and leading practitioner in Science and Technology Park (STP) development with over 25 years’ experience in the sector. My expertise is the development and operation of STPs that are able to grow sustainable communities of interest to both generate successful commercial outcomes and to add value to the regional and national economy. I was the Development and Operations lead at the Cambridge Science Park for ten years, growing the largest science park community in the UK at that time. I am founder-Director of CAM-SCI1, the UK’s leading consultancy in STP development through which I have advised, developed and operated more than 25 science parks and related developments nationally and internationally. Current large- scale projects include Edinburgh Innovation Park, Newcastle Biosphere, Birmingham Life Science Hub and Brisbane Innovation Precinct. Clients include universities, private investor/developers, national and local governments and NHS hospital trusts. I am deeply networked with the innovation-led sector and continue to provide specialist advice to some of the UK’s leading science and technology-based companies. I was a Director of the United Kingdom Science Park Association for four years. See Appendix A. 1.2 Scope In this proof of evidence, I will consider whether the conditions exist for successful delivery of a STP at Inlands Farm and whether the concerns and criticisms raised by objectors are justified.
    [Show full text]
  • Hopkins, 2012)
    City Research Online City, University of London Institutional Repository Citation: Hopkins, M.M., Crane, P.A., Nightingale, P. and Baden-Fuller, C. (2013). Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980--2009. Industrial and Corporate Change, 22(4), pp. 903-952. doi: 10.1093/icc/dtt022 This is the published version of the paper. This version of the publication may differ from the final published version. Permanent repository link: https://openaccess.city.ac.uk/id/eprint/13977/ Link to published version: http://dx.doi.org/10.1093/icc/dtt022 Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to. Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. City Research Online: http://openaccess.city.ac.uk/ [email protected] Industrial and Corporate Change, Volume 22, Number 4, pp. 903–952 doi:10.1093/icc/dtt022 Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980–2009 ,§ Michael M. Hopkins* , Philippa A. Crane**, Paul Nightingaley and Downloaded from Charles Baden-Fullerz This article explores how the UK’s biotech firms have evolved in response to their http://icc.oxfordjournals.org/ financial environment.
    [Show full text]
  • Targeting Cancer
    Antisoma plc Targeting Annual Report and Accounts year ended 30 June 2009 cancer Antisoma plc Chiswick Park Building 5 London W4 5YF UK T: +44 (0)20 3249 2100 F: +44 (0)20 3249 2101 E: [email protected] W: www.antisoma.com Registered in England and Wales, no. 3248123 www.antisoma.com Antisoma plc Annual Report and Accounts 2009 List of advisors Financial advisor and broker Piper Jaffray Ltd One South Place London EC2M 2RB Contents Antisoma is a Auditor PricewaterhouseCoopers LLP 1 Embankment Place Overview London WC2N 6RH 01 Highlights biotechnology 02 Joint Chief Executive’s and Chairman’s statement Registrar 06 Financial review Capita Registrars 08 Board of Directors company Northern House Woodsome Park Fenay Bridge Huddersfield Governance specialising in the West Yorkshire HD8 0GA 10 Directors’ report (including Business review) 13 Corporate social responsibility review development and Legal advisor 15 Report of the Board on remuneration CMS Cameron McKenna LLP 22 Corporate governance Mitre House commercialisation 160 Aldersgate Street London Financial statements EC1A 4DD 25 Independent auditors’ report to the of novel drugs Executive remuneration advisor members of Antisoma plc Hewitt New Bridge Street 26 Consolidated income statement 6 More London Place 26 Consolidated statement of recognised London income and expense for the treatment SE1 2DA 27 Consolidated balance sheet 28 Company balance sheet 29 Consolidated cash flow statement 30 Company cash flow statement of cancer 31 Notes to the consolidated financial statements IBC
    [Show full text]
  • REGENXBIO Inc. (Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 REGENXBIO Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials. ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents REGENXBIO Inc.
    [Show full text]